Clinical Pharmacotherapy and Drug Development for Pulmonary Arterial Hypertension

Author(s): Massimiliano Mule, Marilena Scarabelli, Davide Capodanno, Gian P. Ussia, Corrado Tamburino

Journal Name: Recent Patents on Cardiovascular Drug Discovery (Discontinued)

Volume 6 , Issue 3 , 2011


Pulmonary arterial hypertension (PAH) is a rare, but serious condition which, if untreated, is associated with a poor survival. Currently, even if several trials have led to the approval of many drugs for PAH, there is no established cure for this disease. However, approved drugs for PAH have contributed to significantly improve symptoms, exercise capacity, quality of life and survival of these patients. The aim of this review is to overview the standard treatment of PAH and to give some insights about new treatments that are currently under investigation along with the discussion of recent patents.

Keywords: Endothelin, imatinib, nitric oxide, PAH, prostacyclin, VIP, Prostanoids, Epoprostenol,, Iloprost, ERAs

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [180 - 188]
Pages: 9
DOI: 10.2174/157489011797377059
Price: $65

Article Metrics

PDF: 8